Exonate
Exonate develops innovative, non-invasive eye drop treatments that reduce the effects of Vascular Endothelial Growth Factors to help prevent vision loss caused by retinal diseases.
Non-invasive eye drop treatments that reduce the effects of Vascular Endothelial Growth Factors.
School of Medicine and Health Sciences
Profile
Founded in 2012 as a spin-out from the School of Medicine and Health Sciences, Exonate is a biotech company based in Cambridge and Nottingham. The company develops new, non-invasive medicines to treat eye diseases that can lead to vision loss.
Diseases of the retina are among the leading causes of blindness worldwide. Two of the most common are wet age-related macular degeneration (wet AMD) and diabetic macular oedema (DMO). Both conditions are caused by abnormal growth of blood vessels in the retina, mainly driven by a protein called Vascular Endothelial Growth Factors (VEGF).
Exonate’s treatments work by reducing the effects of VEGF in a new way, helping to slow or stop this harmful blood vessel growth. Their medicines are delivered as eye drops that reach the back of the eye, offering a convenient, non-invasive alternative to injections, laser surgery, or steroid treatments.